医学知识

订阅

MedSci主页 / 所有栏目 / 医学知识

科学家研发用于治疗年龄相关性黄斑变性的眼药水&#160有望取代注射治疗

2017-05-17 cnBeta cnBeta

黄斑变性眼药水
关注

年龄相关性黄斑变性 (AMD) 是一种导致老年人致盲的常见疾病，是一种可引起视力迅速丧失的视网膜退行性病变。患者每月需要用注射液进行治疗。 据外媒报道，现在伯明翰大学的科学家团队开发了一种突破性的新治疗方法，用简单的眼药水可取代此前的注射液。据悉，仅在英国，AMD 就影响了超过 60 万人。而在美国，这种疾病是 50 岁以上人群失明的最常见原因之一。目前的治疗包括直接将药物注射至眼球内。这



年龄相关性黄斑变性 (AMD) 是一种导致老年人致盲的常见疾病，是一种可引起视力迅速丧失的视网膜退行性病变。患者每月需要用注射液进行治疗。 据外媒报道，现在伯明翰大学的科学家团队开发了一种突破性的新治疗方法，用简单的眼药水可取代此前的注射液。

据悉，仅在英国，AMD 就影响了超过 60 万人。而在美国，这种疾病是 50 岁以上人群失明的最常见原因之一。目前的治疗包括直接将药物注射至眼球内。这些注射不仅有损伤眼睛的危险，还令患者非常痛苦。

值得庆幸的是，伯明翰大学的科学家团队开发了这种全新的治疗方法。该小组研发了一种细胞穿透肽（CPP），可以在数分钟内将药物带到眼睛的相关部位。 研究人员使用 CPP 方法将有效和无毒的 AMD 治疗药物滴入到小鼠、大鼠和猪的眼睛中。这种眼药水的生物活性被证明与任何其他可替代的药物相当。

参与这项研究的 Felicity de Cogan 博士表示：“CPP 药物可能通过改变给药选项对 AMD 治疗产生重大影响。与目前的治疗相比，通过眼药水可以有效地自行管理药物，并能避免不利结果和使医疗成本显着降低。”(生物谷 Bioon.com)

版权声明：
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于williamhill asia 医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章，或“williamhill asia 号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系，williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-07-27 crystal0573

    #眼药水#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2018-04-11 shenxlcyp

    #相关性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-10-27 lily1616

    #年龄相关#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 lqvr

    #研发#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 lingqf

    #年龄相关性黄斑变性#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 huangdf

    #变性#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1717482, encodeId=aaa91e1748240, content=<a href='/topic/show?id=9b77e2897ec' target=_blank style='color:#2F92EE;'>#眼药水#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72897, encryptionId=9b77e2897ec, topicName=眼药水)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=043832418746, createdName=crystal0573, createdTime=Thu Jul 27 18:47:00 CST 2017, time=2017-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837240, encodeId=70a1183e240b5, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Wed Apr 11 06:47:00 CST 2018, time=2018-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1933415, encodeId=ccb71933415c6, content=<a href='/topic/show?id=79654901349' target=_blank style='color:#2F92EE;'>#年龄相关#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49013, encryptionId=79654901349, topicName=年龄相关)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Fri Oct 27 08:47:00 CST 2017, time=2017-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300014, encodeId=f65b1300014f4, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376741, encodeId=945513e674158, content=<a href='/topic/show?id=5a7f4901672' target=_blank style='color:#2F92EE;'>#年龄相关性黄斑变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49016, encryptionId=5a7f4901672, topicName=年龄相关性黄斑变性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f3a0392, createdName=lingqf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463529, encodeId=a7cc14635299d, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525082, encodeId=b0571525082ff, content=<a href='/topic/show?id=65e91031337f' target=_blank style='color:#2F92EE;'>#黄斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103133, encryptionId=65e91031337f, topicName=黄斑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=638b11619344, createdName=muzishouyi, createdTime=Fri May 19 05:47:00 CST 2017, time=2017-05-19, status=1, ipAttribution=)]
    2017-05-19 muzishouyi

    #黄斑#

    0

相关威廉亚洲官网

Ophthalmology：地中海饮食可降低年龄相关的黄斑变性发生风险

富含鱼或ω-3脂肪酸的饮食可以预防年龄相关的黄斑变性，所以那些坚持地中海饮食的人群年龄相关的黄斑变性的患病率较低。研究共纳入了5060名研究对象，年龄≥65岁。所有的参与者都接受眼部检查和数字视网膜成像，并使用半定量食物频率问卷来评估其过去的膳食摄入情况以确定他们的地中海饮食评分。最终4753名参与者提供了完整的膳食信息，其中109名参与者有新生血管性AMD，2333名参与者有早期AMD，2262

Nature：重大突破！日本完成世界首例异体诱导性多能干细胞移植临床试验！：临床大发现

3月28日，一名60多岁的日本男子成为了世界上首个接受异体诱导性多能干细胞（iPSCs）移植的人！如果后续研究证明治疗取得了不错的效果的话，那么这毫无疑问是iPSCs临床应用的又一个里程碑，是iPSCs治疗走向标准化和通用化的重要转折点。

Lancet：AAV2载体基因组表达VEGF中和蛋白sFLT01的安全性研究

AAV2-sFLT01具有较好的耐受性和安全性，其疗效需进一步验证

JAMA Ophthalmol：种族因素对老年黄斑变性(AMD)和视觉功能(VSF)的影响

种族因素对黄斑变性和视觉功能有很大影响

N Engl J Med：自体诱导干细胞产生的视网膜细胞用于治疗黄斑变性

研究人员评估了在新生血管性年龄相关性黄斑变性患者中，移植从诱导多能干细胞（iPSCs）中分离的视网膜色素上皮细胞（RPE）片的可行性。iPSC从两名晚期新生血管性年龄相关性黄斑变性患者的皮肤成纤维细胞产生，并分化为RPE细胞。RPE细胞和共同来源的iPSC经过严格的测试。在其中一位患者中进行包括去除新生血管膜，并在视网膜下移植自体iPSC衍生的RPE细胞片的手术。手术后1年，移植片保持完整，矫正视

西雅图视觉与眼科研究协会2016年年会：日本科学家首次让盲人重见光明

日本科学家说他们已经成功完成了世界上首例在人体上从皮肤到眼睛的干细胞移植：来自于患者皮肤的干细胞被移植到她的眼睛上，部分恢复了她失去的视力。这位70岁的女性患者被诊断为老年性黄斑变性，这是老年人视力障碍的首要原因。她在2014年开始接受预备实验。现在，移植两年之后，科学家们公布了结果。研究者们从她的手臂上取了一小块皮肤(直径4毫米)，然后修改了它的干细胞，有效地将它们重新改编为诱导多能干细胞(iP